A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

This study is ongoing, but not recruiting participants.

Study NCT00462761 Information provided by Ambit Biosciences Corporation

First Received: April 17, 2007 Last Updated: May 13, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)